Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

Key Who May Qualify: - Participants must have newly diagnosed and previously untreated AML and be candidates for intensive chemotherapy. - Presence of an NPM1 mutation. - Eastern Cooperative Oncology Group performance status ≤2 (≤1 if \>65 years old); Karnofsky or Lansky ≥40. - Have a life expectancy of ≥3 months as judged by the Investigator. - Negative serum pregnancy test. - Adequate liver, kidney, and cardiac function. Key Who Should NOT Join This Trial: - Diagnosis of active acute promyelocytic leukemia. - Active central nervous system disease. - Fridericia's corrected QT interval (QTcF) \>450 milliseconds at screening, diagnosis or suspicion of Long QT syndrome or family history of Long QT syndrome. - Any gastrointestinal (GI) issue of the upper GI tract likely to affect oral drug absorption or ingestion. - Any concurrent malignancy requiring active therapy (except breast or prostate cancer stable on or responding to endocrine therapy). - Inability to swallow oral medication. - Pregnant or nursing females. - Participant has known active or chronic hepatitis B or active hepatitis C (HCV) infection or human weakened immune system virus (HIV)-positive with detectable viral load. Note: Additional inclusion/exclusion criteria may apply, per protocol. Always talk to your doctor about whether this trial is right for you.